Daiwa Securities Adjusts Price Target on Intuitive Surgical to $460 From $430
Intuitive Surgical Analyst Ratings
Truist Financial Sticks to Its Buy Rating for Intuitive Surgical (ISRG)
Barclays Adjusts Price Target on Intuitive Surgical to $510 From $490
Analysts' Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Intuitive Surgical (ISRG)
Outperform Rating Reaffirmed for Intuitive Surgical on Strong Q2 2024 Performance and Da Vinci 5 Launch Success
Baird Maintains Outperform on Intuitive Surgical, Raises Price Target to $503
Piper Sandler Remains a Buy on Intuitive Surgical (ISRG)
Morgan Stanley Adjusts Price Target on Intuitive Surgical to $475 From $460, Maintains Equalweight Rating
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Nuvation Bio (NUVB)
Strong Performance and Growth Prospects Underpin Buy Rating for Intuitive Surgical
Intuitive Surgical Analyst Ratings
Barclays Remains a Buy on Intuitive Surgical (ISRG)
Baird Adjusts Price Target on Intuitive Surgical to $487 From $436, Maintains Outperform Rating
Intuitive Surgical Analyst Ratings
BTIG Adjusts Price Target on Intuitive Surgical to $459 From $451, Maintains Buy Rating
Mizuho Adjusts Price Target on Intuitive Surgical to $440 From $390
Intuitive Surgical Analyst Ratings
Citigroup Adjusts Price Target on Intuitive Surgical to $512 From $462
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Catalyst Pharma (CPRX) and Eli Lilly & Co (LLY)